A shortage of late-stage capital pushes the biggest prizes into US hands
Faster trials and lower costs are drawing western multinationals as they seek new treatments
Big pharma groups look to boost line-up as they confront patent cliff for blockbuster treatments
US company is attempting to acquire the maker of a new treatment for pancreatic cancer
Dark Blue Therapeutics was spun out of an Oxford university incubator in 2022
More drugs entering middle or late-stage development drive up demand
John Arnold parlayed windfall from natural gas bets into a foundation that is challenging medicine approvals
He Jiankui’s experiment with human embryos caused global outrage. Can he make an unlikely comeback?
Zealand Pharma chief says next-generation obesity drugs will need to be longer lasting and better tolerated
Tuberculosis rethink; fears for HIV progress; AI potential against resistant bacteria; UK boosts wastewater tests; rebuilding immunity to superbugs; insect-borne diseases threat; Chagas disease explainer
Wave of M&A fuels rally as big pharma groups hunt for blockbusters ahead of patent cliff
Research shows synthetic chromosomes can be transferred to human cells with potential to improve viral resistance
Sam Altman declares ‘code red’ as global rivals and new AI entrants narrow OpenAI’s early lead
The biopharma industry is booming following record investment and improved supply chains
PopEVE system outperformed rivals such as Google DeepMind’s AlphaMissense
Maker of Covid-19 shots has slumped since pandemic as people turn against vaccines
Major companies are reducing research on new medicines for illnesses that affect billions of people
Pharma group hopes acquisition will help to offset losses from expiring patents on blockbuster drugs
Bidding war goes down to wire for company whose lead drug is potential alternative to vaccines for vulnerable patients
The tussle between the two drugmakers has spread from the boardroom to the courtroom to the corridors of Washington
Biotech says it opted for revised offer from US pharma company after rival Novo bid raised antitrust concerns
US judge declines to intervene in fray because process ‘is creating value for Metsera stockholders’
Novo and Metsera deny Pfizer’s arguments
FTC fast-tracks antitrust approval of earlier deal in sign Washington could weigh in on takeover battle with Novo Nordisk
Groups will need to buy mature biotechs to replace revenue lost to generic competitors
